30 November 2009 in Journal of Medical Virology
24 November 2017 in Oncology Letters
Nuclear respiratory factor‑1 (Nrf1) and mitochondrial transcription factor A (TFAM) are involved in the regulation of a variety of mitochondrial functional genes, which are associated with decreased sensitivity of tumor cells to chemotherapy. However, the expression status of Nrf1 and TFAM, as well as their clinical significance in breast cancer, is unknown. In the present study, tumor tissues and corresponding adjacent normal tissues were collected from 336 patients with breast cancer, and Nrf1 and TFAM expression was analyzed by immunohistochemistry using a tissue microarray. Expression of Nrf1 and TFAM was significantly increased in breast cancer tissue compared with adjacent normal tissues. In addition, patients positive for Nrf1 or TFAM had a poorer clinical prognosis than patients who were negative, and those positive for Nrf1 and TFAM had the shortest survival time. These results suggest that Nrf1 and TFAM are potential biomarkers for the determination of individualized therapy and the prognosis of breast cancer, and molecular targeting of Nrf1 and TFAM is a promising strategy for the sensitization of breast cancer cells to chemotherapeutics.
8 April 2016 in International Journal of Molecular Medicine
Acute myeloid leukemia (AML) is an aggressive clonal malignancy of hematopoietic progenitor cells with a poor clinical outcome. The resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating AML. Combining valproic acid (VPA) with other anti-leukemic agents has previously been noted as a useful and necessary strategy which can be used to specifically induce anticancer gene expression. In the present study, we demonstrated the synergistic antileukemic activities between VPA and cytarabine (Ara‑C) in a retrovirus-mediated murine model with MLL-AF9 leukemia, three leukemia cell lines (THP-1, K562 and HL-60) and seven primary human AML samples. Using RT-qPCR, we noted that the combination of VPA and Ara‑C significantly upregulated Bax expression and led to the arrest of leukemia cell proliferation, sub-G1 DNA accumulation and cell apoptosis, as demonstrated by flow cytometric analysis. Significantly, further experiments revealed that knockdown of Bax expression prevented VPA and Ara‑C‑induced cell apoptosis in THP-1 cells. The results of our present study demonstrated the synergistic antileukemic effect of combined VPA and Ara‑C treatment in AML, and thus we suggest that VPA be used an alternative treatment for AML.
12 March 2024 in Research Square
Background: The presence of the RUNX1::RUNX1T1 fusion gene in patients diagnosed with acute myeloid leukemia (AML) subtype is often indicated by distinctive morphological features in myeloblasts from bone marrow (BM) smears. This study aims to evaluate the capacity of artificial intelligence (AI) to identify specific genetic abnormalities based solely on morphological characteristics. The intent is to investigate a non-invasive, cost-effective, and efficient preliminary screening method prior to the application of molecular biological assays. Methods: This multicenter trial included 205 patients diagnosed with AML, of which 75 were AML with RUNX1::RUNX1T1 fusion. A dataset of 65,039 myeloblasts images collected from the BM smears of these patients was compiled for model training, testing, and validation. The study also undertook a comparative analysis of the discrepancies between manual microscopy and AI-based identification. Results: The model demonstrated proficiency in adapting to varied clinical scenarios by applying two different threshold values. Under the threshold of 0.59, the testing and validation cohorts showed sensitivities of 92.86% and 95.65%, with corresponding accuracies of 87.04% and 71.88%. Conversely, by setting the threshold at 0.88, specificities of 92.31% and 92.68% were achieved, along with accuracies of 88.89% and 90.63%. Regardless of the threshold, the AI model consistently outperformed manual microscopy (average accuracy: 50.00%). Conclusion: The model demonstrates a significant capability to discern underlying RUNX1::RUNX1T1 genetic alterations from the morphological attributes of BM nucleated cells with a precision surpassing human observation. This providing a valuable tool highlights its potential for enhancing diagnostic efficiency in clinical practice.
1 October 2026 in Genes & Diseases
18 March 2020 in Cytometry Part B: Clinical Cytometry
Cytometry Part B: Clinical Cytometry focuses on the development and applications of cellular system analysis and array based technologies as applied to clinical practice and translational research. This journal also covers relevant techniques such as flow cytometry, image cytometry, beadbased and slide-based array analyses, as well as other cell-based spectroscopic analyses. In addition, Clinical Cytometry publishes clinical and translational investigations that identify and validate the features and molecules important in diagnosis, prognosis, and therapeutic management of patients